Hemo (China) Biotechnology Co., Ltd

Hemo (China) Biotechnology Co., Ltd

Hemo (China) Biotechnology Co., Ltd was founded in 2017 with a registered capital of USD 23,191,100 and located at Block A, Torch Innovation and Entrepreneurship Base, No. 213 Torch Road, Yiyuan Street, Torch High-Tech Industrial Development Zone, Weihai City, Shandong Province, with a total investment of USD 60 million. WoMu (China) Bioengineering Co., Ltd. is a medical device research, development and manufacturing enterprise committed to vascular interventional therapy and the whole management of stroke. The main products include intracranial suction catheter, endovascular access catheter, neurovascular balloon catheter, etc.

The company has more than 150 employees, including nearly 50 R&D personnel. There are more than 20 products in research and development, involving ischemic stroke treatment devices, hemorrhagic stroke treatment devices, access devices and peripheral nerve interventional therapy products and other interventional fields, of which more than 10 R&D products have obtained the medical device registration certificate, and it has undertaken 4 provincial and ministerial level research projects including Shandong Province's key R&D program, and has set up 2 municipal research platforms, such as Weihai City Key Laboratory and Weihai City Engineering Research Center. The company's intracranial thrombus suction catheter product broke the import monopoly and was the first similar product approved in China, and the product and its relying patent won the second prize of Shandong Old and New Energy Transformation High Value Patent Cultivation Competition in 2021. In 2022, the company participated in the 11th China Innovation and Entrepreneurship Competition with its product Rapamycin drug-coated balloon catheter, and was honored with the title of excellent enterprise at one fell swoop.